Cargando…

Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant

The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Błaszczuk, Agata, Michalski, Aleksander, Sikora, Dominika, Malm, Maria, Drop, Bartłomiej, Polz-Dacewicz, Małgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612121/
https://www.ncbi.nlm.nih.gov/pubmed/36298593
http://dx.doi.org/10.3390/vaccines10101728
_version_ 1784819700466712576
author Błaszczuk, Agata
Michalski, Aleksander
Sikora, Dominika
Malm, Maria
Drop, Bartłomiej
Polz-Dacewicz, Małgorzata
author_facet Błaszczuk, Agata
Michalski, Aleksander
Sikora, Dominika
Malm, Maria
Drop, Bartłomiej
Polz-Dacewicz, Małgorzata
author_sort Błaszczuk, Agata
collection PubMed
description The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies.
format Online
Article
Text
id pubmed-9612121
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96121212022-10-28 Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant Błaszczuk, Agata Michalski, Aleksander Sikora, Dominika Malm, Maria Drop, Bartłomiej Polz-Dacewicz, Małgorzata Vaccines (Basel) Article The SARS-CoV-2 virus caused a worldwide COVID-19 pandemic. So far, 6,120,834 confirmed cases of COVID-19 with 116,773 deaths have been reported in Poland. According to WHO, a total of 54,662,485 vaccine doses have been administered. New variants emerge that become dominant. The aim of this study was a comparison of antibody level after infection caused by Delta and Omicron variants. The study included 203 persons who underwent mild COVID-19 despite two doses of vaccine. The obtained results indicate that a significantly lower titer was observed in patients with the Omicron variant infection. Therefore, these patients may be at risk of reinfection with new strains of the Omicron variant. Due to the possibility of reinfection, booster vaccinations are necessary. Further epidemiological and clinical studies are necessary to develop new prevention strategies. MDPI 2022-10-16 /pmc/articles/PMC9612121/ /pubmed/36298593 http://dx.doi.org/10.3390/vaccines10101728 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Błaszczuk, Agata
Michalski, Aleksander
Sikora, Dominika
Malm, Maria
Drop, Bartłomiej
Polz-Dacewicz, Małgorzata
Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
title Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
title_full Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
title_fullStr Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
title_full_unstemmed Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
title_short Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant
title_sort antibody response after sars-cov-2 infection with the delta and omicron variant
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612121/
https://www.ncbi.nlm.nih.gov/pubmed/36298593
http://dx.doi.org/10.3390/vaccines10101728
work_keys_str_mv AT błaszczukagata antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant
AT michalskialeksander antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant
AT sikoradominika antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant
AT malmmaria antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant
AT dropbartłomiej antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant
AT polzdacewiczmałgorzata antibodyresponseaftersarscov2infectionwiththedeltaandomicronvariant